在戒酒后的酒精使用障碍中,运动对认知障碍的益处
Zhen Lyu1,2, Zhi-Gang Gong1, Min-Xia Huang3
1Key Lab of Aquatic Sports Training Monitoring and Intervention of General Administration of Sport of China, Faculty of Physical Education, Jiangxi Normal University, Nanchang, China.
FEBS open bio
|July 25, 2024
概括
有氧运动可以改善戒酒后患有酒精使用障碍 (AUD) 的小鼠的学习和记忆. 这种干预可以恢复大脑化学物质和海马体大小,帮助认知恢复.
科学领域:
- 神经科学是一个神经科学.
- 行为科学 行为科学
- 运动生理学 运动生理学
背景情况:
- 长时间的饮酒会导致持续的认知缺陷,即使在戒酒后.
- 酒精使用障碍 (AUD) 显著影响学习和记忆功能.
- 了解缓解这些缺陷的干预措施对于治疗至关重要.
研究的目的:
- 为了研究有氧运动对AUD小鼠戒断后学习和记忆的影响.
- 评估海马单胺神经递质和脑衍生神经营养因子 (BDNF) 水平的变化.
- 探索运动作为治疗酒精诱导认知障碍的治疗策略的潜力.
主要方法:
- 使用慢性间歇性酒精蒸汽和注射建立了一个酒精使用障碍 (AUD) 鼠标模型.
- 作为有氧运动干预的一部分,小鼠接受了跑步机训练.
- 用莫里斯水迷宫和开放场地测试来评估认知功能.
- 通过ELISA量化了海马体中多巴胺,上腺素,血清素和BDNF的水平.
主要成果:
- 在AUD小鼠的认知功能在戒酒后没有完全恢复到正常水平.
- 有氧运动显著提高了AUD小鼠的学习和记忆能力.
- 运动干预导致海马单胺神经递质水平恢复,BDNF度增加.
- 有氧运动与AUD小鼠海马体质量的增加有关.
结论:
- 有氧运动在改善与酒精使用障碍相关的认知缺陷方面表现出有效性.
- 运动的有益影响可能来自于恢复神经递质平衡和海马中的神经营养支持.
- 有氧运动是一个有希望的,非药物治疗方法,用于管理AUD的认知障碍.
相关概念视频
01:30Cognitive Development During Adulthood
76
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
76
01:27CNS Depressants: Alcohol and Nicotine
193
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
193
01:22Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172
01:20Exercise and Cardiovascular Response
769
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
769
01:26Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
114
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
114